Departamento de Cirugía Cardiovascular y Torácica, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina.
Ann Thorac Surg. 2013 Jul;96(1):279-85. doi: 10.1016/j.athoracsur.2013.02.037. Epub 2013 Apr 18.
There are no data that compare the clinical presentation and results of surgical lung biopsy (SLB) for diffuse lung disease (DLD) in lung transplant patients, in contrast to individuals with other type of solid organ grafts. Our objective was to compare the clinical picture, radiologic pattern, pathology results, and outcomes of SLB for DLD in these two subsets of patients.
We retrospectively reviewed the clinical records of transplant patients undergoing SLB for DLD at our institution between 2004 and 2011. Patients with lung transplants and those with other transplants were compared.
During the study period, 1,232 solid organ transplants were done at our institution. Of these, 49 patients (4%) had DLD that needed SLB for diagnosis, and 24 of these patients had a lung transplant. Dyspnea and a radiologic reticular pattern were more frequent in lung transplant patients, 21 of 24 vs 11 of 25 (p = 0.001) and 14 of 24 vs 7 of 25 (p = 0.03), respectively. Although postoperative complications and in-hospital deaths were more common in lung transplant patients, the differences were not statistically significant. Having the SLB performed for diagnosis, as opposed to being conducted for DLD that did not improve on medical treatment, had a protective effect on multivariate analysis (hazard ratio, 0.39; 95% confidence interval, 0.16 to 0.96; p = 0.042). A prior lung transplant was the only independent predictor of survival (hazard ratio, 4.62; 95% confidence interval, 1.53 to 13.92, p = 0.006).
It is relatively uncommon for a solid organ transplant patient with DLD to require a SLB. Clinical and radiologic presentation differ in patients with lung transplants compared with other transplants. Postoperative outcomes are not significantly different between the groups. SLB performed early in the course of the disease might be beneficial. Having a lung transplant is a significant negative predictor of survival.
目前尚无数据比较肺移植患者与其他实体器官移植患者弥漫性肺疾病行外科肺活检(SLB)的临床表现和结果。我们的目的是比较这两组患者的临床情况、影像学模式、病理结果和 SLB 结果。
我们回顾性分析了 2004 年至 2011 年在我院行 SLB 诊断弥漫性肺疾病的移植患者的临床记录。比较了肺移植患者和其他移植患者。
在研究期间,我院共进行了 1232 例实体器官移植。其中,49 例(4%)弥漫性肺疾病患者需要 SLB 诊断,其中 24 例为肺移植患者。呼吸困难和影像学网状模式在肺移植患者中更为常见,分别为 24 例中的 21 例(24/24 比 25 例中的 11 例,p=0.001)和 14 例(24/24 比 25 例中的 7 例,p=0.03)。尽管肺移植患者术后并发症和住院死亡更为常见,但差异无统计学意义。与未改善的药物治疗相比,诊断性 SLB 对多因素分析有保护作用(风险比,0.39;95%置信区间,0.16 至 0.96;p=0.042)。既往肺移植是唯一的独立生存预测因素(风险比,4.62;95%置信区间,1.53 至 13.92,p=0.006)。
实体器官移植患者弥漫性肺疾病需要 SLB 的情况相对较少。与其他移植患者相比,肺移植患者的临床表现和影像学表现不同。两组患者的术后结局无显著差异。疾病早期行 SLB 可能有益。肺移植是生存的显著负预测因素。